公开(公告)号：US20170100340A1

公开(公告)日：2017-04-13

申请号：US15181114

申请日：2016-06-13

Applicant: Vertex Pharmaceuticals Incorporated

Inventor： Eleni DOKOU ,  Shahla JAMZAD ,  John P. CAESAR, JR. ,  Majed FAWAZ ,  Laura DAS ,  Chong-Hui GU ,  Patricia Nell HURTER ,  Meghna Jai ISRANI ,  Meghan M. JOHNSTON ,  Dragutin KNEZIC ,  Andrew G. KUZMISSION ,  HongRen WANG

IPC: A61K9/20 ,  A61K31/47

CPC classification number: A61K9/205 ,  A61K9/143 ,  A61K9/145 ,  A61K9/146 ,  A61K9/1611 ,  A61K9/1617 ,  A61K9/1623 ,  A61K9/1652 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/2072 ,  A61K9/2077 ,  A61K9/4808 ,  A61K9/485 ,  A61K9/4858 ,  A61K9/4866 ,  A61K31/47 ,  A61K47/02 ,  A61K47/12 ,  A61K47/20 ,  A61K47/26 ,  A61K47/38 ,  C07D215/56

Abstract: The present invention relates to pharmaceutical compositions containing a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide including formulations of the solid dispersions into powders, granules and mini-tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating cystic fibrosis employing the pharmaceutical composition.

公开(公告)号：US20190274959A1

公开(公告)日：2019-09-12

申请号：US16299675

申请日：2019-03-12

Applicant: Vertex Pharmaceuticals Incorporated

Inventor： Eleni DOKOU ,  Shahla JAMZAD ,  John P. CAESAR, JR. ,  Majed FAWAZ ,  Laura DAS ,  Chong-Hui GU ,  Patricia Nell HURTER ,  Meghna Jai ISRANI ,  Meghan M. JOHNSTON ,  Dragutin KNEZIC ,  Andrew G. KUZMISSION ,  HongRen WANG

IPC: A61K9/20 ,  A61K31/47 ,  A61K9/16 ,  A61K9/14 ,  A61K47/02 ,  A61K47/38 ,  A61K47/20 ,  A61K47/26 ,  A61K9/48 ,  C07D215/56 ,  A61K47/12

Abstract: The present invention relates to pharmaceutical compositions containing a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide including formulations of the solid dispersions into powders, granules and mini-tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating cystic fibrosis employing the pharmaceutical composition.

公开(公告)号：US20240156738A1

公开(公告)日：2024-05-16

申请号：US18355475

申请日：2023-07-20

Applicant: Vertex Pharmaceuticals Incorporated

Inventor： Eleni DOKOU ,  Shahla JAMZAD ,  John P. CAESAR, JR. ,  Majed FAWAZ ,  Laura DAS ,  Chong-Hui GU ,  Patricia Nell HURTER ,  Meghna Jai ISRANI ,  Meghan M. JOHNSTON ,  Dragutin KNEZIC ,  Andrew G. KUZMISSION ,  HongRen WANG

IPC: A61K9/20 ,  A61K9/14 ,  A61K9/16 ,  A61K9/48 ,  A61K31/47 ,  A61K47/02 ,  A61K47/12 ,  A61K47/20 ,  A61K47/26 ,  A61K47/38 ,  C07D215/56

CPC classification number: A61K9/205 ,  A61K9/143 ,  A61K9/145 ,  A61K9/146 ,  A61K9/1611 ,  A61K9/1617 ,  A61K9/1623 ,  A61K9/1652 ,  A61K9/2009 ,  A61K9/2013 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/2072 ,  A61K9/2077 ,  A61K9/4808 ,  A61K9/485 ,  A61K9/4858 ,  A61K9/4866 ,  A61K31/47 ,  A61K47/02 ,  A61K47/12 ,  A61K47/20 ,  A61K47/26 ,  A61K47/38 ,  C07D215/56

Abstract: The present invention relates to pharmaceutical compositions containing a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide including formulations of the solid dispersions into powders, granules and mini-tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating cystic fibrosis employing the pharmaceutical composition.

公开(公告)号：US20220241206A1

公开(公告)日：2022-08-04

申请号：US17475622

申请日：2021-09-15

Applicant: Vertex Pharmaceuticals Incorporated

Inventor： Eleni DOKOU ,  Shahla JAMZAD ,  John P. CAESAR, JR. ,  Majed FAWAZ ,  Laura DAS ,  Chong-Hui GU ,  Patricia Nell HURTER ,  Meghna Jai ISRANI ,  Meghan M. JOHNSTON ,  Dragutin KNEZIC ,  Andrew G. KUZMISSION ,  HongRen WANG

IPC: A61K9/20 ,  A61K31/47 ,  A61K9/16 ,  A61K9/48 ,  C07D215/56 ,  A61K9/14 ,  A61K47/02 ,  A61K47/12 ,  A61K47/20 ,  A61K47/26 ,  A61K47/38

Abstract: The present invention relates to pharmaceutical compositions containing a solid dispersion of N-[2,4-Bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide including formulations of the solid dispersions into powders, granules and mini-tablets, methods for manufacturing and processing the powders, granules and mini-tablets, and methods for treating cystic fibrosis employing the pharmaceutical composition.